ClinicalTrials.gg
RecruitingNCT07947550Updated Nov 19, 2026

Diagnostic Accuracy of Combined Perfusion Index, Internal Jugular Vein Collapsibility Index and Cardiac Index in Predicting Post-Spinal Hypotension During Elective Cesarean Section

An observational study in Cesarean Delivery Under Neuraxial Anesthesia, sponsored by Menoufia University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Menoufia University · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

compare Perfusion Index with Internal Jugular Vein Collapsibility Index (IJVCI) as a predictor for post-spinal hypotension in parturient undergoing elective caesarean section.

Read the detailed description
  • Pre-anesthetic evaluation (History-Investigation - Examination) the day before surgery.
  • NPO: 8 hours for solids, 2 hours for clear fluids.
  • Pre-medication: Ranitidine 50 mg IV + Metoclopramide 10 mg IV, 30 minutes before anesthesia.
  • 18-G IV cannula in the non-dominant forearm.
  • Standard monitoring in the operating room: pulse oximetry (SpO2), NIBP, and ECG.
  • Baseline measurements (HR, SBP, DBP, MAP, SpO2, PI, CI, IJVCI) recorded in the supine position with 15 degree left lateral tilt.
  • All indicators will be measured in a single group before spinal anesthesia and comparisons will be made for the most sensitive maneuver in prediction of post spinal hypotension.
  • Cardiac Index (CI) will be measured using cardiometry before spinal anesthesia.
  • Perfusion Index (PI) is measured (Three consecutive readings are recorded at 1-minute intervals, will be repeated with another reading after delivery of baby).• The cut-off applied is: -
  • 3.5 or less (low risk for hypotension)
  • Greater than 3.5 (high risk for hypotension)
  • Internal Jugular Vein Collapsibility Index will be measured by Ultrasonographic assessment and is performed by using a 6-10 MHz linear ultrasound probe. (The patient is placed supine with 15 degree left lateral tilt, The probe is positioned horizontally at the right side of the neck at the level of the middle thyroid cartilage, obtaining a transverse view of the right IJV. M-mode imaging during both spontaneous and deep breathing).
  • Anteroposterior diameters of the IJV were estimated during the respiratory cycle. The IJV collapsibility index (IJVCI) was estimated via the following equation: Maximum diameter - lowest diameter/maximum diameter) 100% .
  • The mean of three consecutive measurements is recorded for each breathing mode in quite respiratory cycle.
  • Images will be saved for offline analysis.
  • The cut-off applied is:

IJVCI \< 35-38% → lower risk of post-spinal hypotension IJVCI ≥ 38-40% → higher likelihood of hypotension after spinal anesthesia in CS.

  • Spinal anesthesia with intrathecal drug regimen 10-12 mg of 0.5% hyperbaric bupivacaine plus 25 micrograms (mic) Fentanyl].
  • Co-loading with Ringer's lactate at 10ml/Kg will be administrated, along with spinal anesthesia placement .Data Collection

Baseline:

  1. Patient demographic data (age, ASA physical status, comorbidities, current medications, and BMI).
  2. Hemodynamics (Heart rate- Mean Arterial Blood Pressure - Systolic Blood Pressure -Oxygen Saturation) baseline reading before induction of spinal anesthesia.
  3. Preoperative IJVCI measurement by ultrasound imaging in supine position.
  4. Preoperative Perfusion Index reading.
  5. Preoperative Cardiac index reading.

Intraoperative:

  1. Hemodynamic parameters (SBP, DBP, MAP, HR, SpO2) are recorded: -

    • Every 1 minute for the first 10 minutes,
    • Every 3 minutes until delivery,
    • Every 5 minutes thereafter until end of surgery.
  2. Total phenylephrine dose in microgram \& Total Ephedrine dose (mg) [if persistent hypotension].
  3. Total IV fluid volume (mL)
  4. Total Blood loss (mL)
  5. Total Urine output (mL)
  6. Time from spinal block to delivery (min)
  7. Total time of surgery.
  8. All adverse events (nausea, vomiting, hypotension, bradycardia, oxygen desaturation) are recorded throughout.

Definition of Outcomes All outcome definitions are pre-specified and uniformly applied across all patients: -

  • Post-spinal hypotension: A fall in systolic blood pressure (SBP) below 90 mmHg.
  • Episodes are recorded from the time of spinal injection until delivery of the baby.
  • Bradycardia: Heart rate below 50 beats per minute requiring pharmacological treatment with atropine 0.01 mg/kg IV.

Treatment of PSH

  • First-line: 200 mL Ringer's lactate rapid IV infusion.
  • If SBP remains below 90 mmHg phenylephrine 25-100 microgram if persistent hypotension gives Ephedrine 5-15 mg IV bolus.
  • Bradycardia (HR \< 50 bpm): Atropine 0.01 mg/kg IV.
  • All vasopressor doses and additional fluid volumes administered are recorded.
02

Conditions studied

  • Cesarean Delivery Under Neuraxial Anesthesia
03

In context

Lead sponsor

Menoufia University is the lead sponsor of 202 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults undergoing Elective Cesarean Section at Menoufia University Hospitals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Full-term pregnant women undergoing elective cesarean section under spinal anesthesia (gestational age >= 37 weeks), singleton pregnancy.

    • Age: 18-40 years.
    • , II.
    • : 18.5-35 kg/m2.

Exclusion criteria

Exclusion Criteria:

    • Patient refusal or inability to provide .

      • Emergency cesarean section.
      • Known to spinal anesthesia (coagulopathy, local infection, elevated ICP).
      • Baseline hypotension (SBP \< 100 mmHg) prior to spinal anesthesia.
      • Hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, eclampsia).
      • Placenta previa or antepartum hemorrhage.
      • Multiple pregnancy or known fetal abnormality.
      • > 35 kg/m2.
      • Pre-existing cardiovascular, cerebrovascular, or significant pulmonary disease.
      • Gestational diabetes or uncontrolled systemic disease.
      • \< 8 g/dL or known haemoglobinopathy.
      • Peripheral vascular disease affects pulse oximetry signal quality.
      • More than two attempts at lumbar puncture or failed.
      • Inadequate spinal block.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Perfusion Index (PI) group measured by pulse oximeter

    * Perfusion Index (PI) is measured using a validated multi-parameter monitor with a pulse oximetry module (Mindray uMEC 12 or equivalent). * The probe is placed on the right index finger in the supine position before induction of spinal anesthesia block. * Three consecutive readings are recorded at 1-minute intervals. * These steps will be repeated with another reading after delivery of baby. * Then the mean value is used as the baseline PI. * The cut-off applied is: - * 3.5 or less (low risk for hypotension) * Greater than 3.5 (high risk for hypotension)

    Device: pulse oximeter to measure Perfusion Index (PI)

  • Internal Jugular Vein Collapsibility Index group will be measured by ultrasonography

    * Internal Jugular Vein Collapsibility Index will be measured by Ultrasonographic assessment and is performed by using a 6-10 MHz linear ultrasound probe. * The patient is placed supine with 15 degree left lateral tilt. * The probe is positioned horizontally at the right side of the neck at the level of the middle thyroid cartilage, obtaining a transverse view of the right IJV. M-mode imaging during both spontaneous and deep breathing. * Anteroposterior diameters of the IJV were estimated during the respiratory cycle. The IJV collapsibility index (IJVCI) was estimated via the following equation: Maximum diameter - lowest diameter/maximum diameter) 100% \[20\]. * The mean of three consecutive measurements is recorded for each breathing mode in quite respiratory cycle . * Images will be saved for offline analysis. * The cut-off applied is: IJVCI \< 35-38% → lower risk of post-spinal hypotension IJVCI ≥ 38-40% → higher likelihood of hypotension after

Interventions

  • Devicepulse oximeter to measure Perfusion Index (PI)

    is measured using a validated multi-parameter monitor with a pulse oximetry module (Mindray uMEC 12 or equivalent). * The probe is placed on the right index finger in the supine position before induction of spinal anesthesia block. * Three consecutive readings are recorded at 1-minute intervals. * These steps will be repeated with another reading after delivery of baby. * Then the mean value is used as the baseline PI. * The cut-off applied is: - * 3.5 or less (low risk for hypotension) * Greater than 3.5 (high risk for hypotension)

06

What researchers measure

Primary outcomes

  1. compare the diagnostic accuracy assessed by ROC curve analysis between Perfusion Index (PI) & Internal Jugular Vein Collapsibility Index (IJVCI) combined with Cardiac Index (CI) in predicting post-spinal hypotension in elective CS patients.

    Time frame: • Three consecutive readings are recorded at 1-minute intervals. • These steps will be repeated with another reading after delivery of baby.

Secondary outcomes

  1. measure systolic arterial blood pressure changes after spinal anesthesia.

    Time frame: immediately after spinal anesthesia

  2. Total ephedrine dose or phenylephrine dose /milligram.

    Time frame: throughout the operation

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07947550
Responsible party
Nevine Mostafa Soliman (assistant professor, Menoufia University) — Principal investigator
First posted
Nov 19, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Nevine Soliman, MD
Contact
mostafanevine@gmail.com
201128861471

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion